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Plasma cell-free DNAAbstract Background: Prostate cancer (PC) is the most common cancer affecting men, it accounts
for 29% of all male cancer and 11% of all male cancer related death. DNA is normally released
from an apoptotic source which generates small fragments of cell-free DNA, whereas cancer
patients have cell-free circulating DNA that originated from necrosis, autophagy, or mitotic catas-
trophe, which produce large fragments.
Aim of work: Differentiate the cell free DNA levels (cfDNA) and its integrity in prostate cancer
patients and control group composed of benign prostate hyperplasia (BPH) and healthy persons.
Methodology: cf-DNA levels were quantiﬁed by real-time PCR ampliﬁcation in prostate cancer
patients (n = 50), (BPH) benign prostate hyperplasia (n = 25) and healthy controls (n = 30)
using two sets of ALU gene (product size of 115 bp and 247-bp) and its integrity was calculated
as a ratio of qPCR results of 247 bp ALU over 115 bp ALU.
Results: Highly signiﬁcant levels of cf-DNA and its integrity in PC patients compared to BPH.
Twenty-eight (56%) patients with prostate cancer had bone metastasis. ALU115 qpcr is superior
to the other markers in discriminating metastatic patients with a sensitivity of 96.4% and a speci-
ﬁcity of 86.4% and (AUC= 0.981)
Conclusion: ALU115 qpcr could be used as a valuable biomarker helping in identifying high risk
patients, indicating early spread of tumor cells as a potential seed for future metastases.
 2016 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Prostate Cancer is the sixth most common cancer in the world.
Prostate cancer (PC) is the sixth most common type of cancer
in the world. It is the highest cancer in elderly males
(>70 years of age) with substantial impact on morbidity and
236 A. Fawzy et al.mortality rates. It accounts for 29% of all male cancer and
11% of male cancer related death [1].
Prostate cancer patients’ faces multistep challenges during
the course of the disease. At diagnosis using prostate speciﬁc
antigen (PSA) test with its low speciﬁcity result in a lack of
cancer detection in a signiﬁcant proportion of patients [2]. In
contrast, men receiving radical treatment for presumed locally
conﬁned prostate cancer often develop disease relapse post
treatment, and in the majority of these patients the disease
was more extensive than it appeared pre-treatment [3]. Early
occult dissemination of PC cells from the primary tumor
through the bloodstream to secondary organs is a critical step
in tumor progression.
Dissemination of PC cell from primary tumor may occur
due to the overexpression of MUC1-C oncoprotein, which
enhances the epithelial-mesenchymal transition (EMT) and
therefore promoting metastasis in epithelium-derived carci-
noma. [4] Similarly, MYC oncogene is also responsible for
the development and progression of prostate cancer [5] and
changes in promoter hypermethylation are driven by DNA
methyltransferase (DNMTs) [6]. But detection of these mark-
ers requires sophisticated methods and has been studied on cell
lines and cultures.
Currently, repeated measurements of PSA blood serum
levels are done after the primary treatment of PC (e.g., surgery
or radiotherapy). However, the increase in PSA concentrations
(also called biochemical recurrence) cannot distinguish
between a local or metastatic relapse. In addition, even if overt
metastases are subsequently conﬁrmed by current imaging
technologies (e.g., bone scans), the patient has become already
incurable [2]. Thus, a biomarker which can be used as a valu-
able tool in identifying high risk patients, indicating early
spread of tumor cells as a potential seed for future metastases
is highly needed.
In healthy individuals, the main source of free circulating
DNA is apoptotic cells which release uniformly truncated
DNA fragments (185–200 base pair) in length, in contrast
to DNA released from malignant cells via necrosis or mitotic
catastrophe, autophagy and mitochondrial catastrophe, which
varies in size because of random and incomplete digestion of
genomic DNA, which leads to raised levels of circulating
cell-free DNA (cfDNA) with longer fragments in serum or
plasma. [7]. The use of plasma/serum cell-free DNA has
attracted the interest of clinicians in oncology [8], prenatal
diagnosis [9], and hematology [10]. Patients with cancer have
a higher concentration of circulating cell-free DNA as com-
pared to healthy people [8], since cfDNA in cancer patients
often bears similar genetic and epigenetic features to the
related tumor DNA, there is evidence that some of the cfDNA
originates from tumoral tissue. It is possible that circulating
cell-free DNA may serve as a non-invasive, rapid and sensitive
biomarker for molecular diagnosis, prognosis and monitoring
treatment response in various types of cancers [11,12]. The use
of cfDNA and DNA integrity has been studied in several stud-
ies including Prostate Cancer [13–15].
Most of the plasma DNA of normal individuals belongs to
the Arthrobacter luteus (ALU) repeat family. The ALU
sequences are about 300 base pairs long and are therefore clas-
siﬁed as short interspersed elements (SINEs) typically 300
nucleotides in length, that account for more than 10% of the
human genome, among the class of repetitive DNA elements.
[16]. The ALU is the most abundant repeated sequence inthe human genome, with a copy number of 1.4  106 per gen-
ome. ALU elements multiply within the genome in a retropo-
sition process through RNA polymerase III-derived
transcripts from evolution. [17]. Several studies used ALU
amplicons and Cell-free circulating DNA integrity which is
the ratio of repeated sequences of ALU (247 and 115 bp)
[15,18]. The ALU 115 primers amplify small fragments (trun-
cated by apoptosis) and the ALU 247 primer ampliﬁes longer
DNA fragments. Therefore, using direct q-PCR of ALU
repeats with properly designed primer sets can detect as little
as 0.01 pg of DNA (equivalent to about 1/300 of the genome
in a single cell) with high linearity. Moreover, using plasma
directly as template set can dramatically increase the sensitivity
of size-dependent DNA measurement by eliminating artifacts
associated with DNA puriﬁcation [18].
The present communication aimed to differentiate the cell
free DNA levels (cfDNA) and its integrity in prostate cancer
patients and control group composed of benign prostate
hyperplasia (BPH) and healthy persons. And study the rela-
tionships between the results and the clinicopathological ﬁnd-
ings to evaluate the prognostic value of these markers in the
detection of included cases.
Patients and methods
This is a cross sectional study that included 105 cases gathered
during the time period from February 2014 to June 2015. A
group of 50 patients were newly diagnosed Prostate Cancer.
They were recruited from the oncology outpatient clinic at
National Cancer Institute – Cairo University. The stage of
prostate cancer was classiﬁed using the TNM staging system,
according to the American Joint Committee on Cancer
(AJCC).
Eligibility criteria for patient selection in our study were as
follows: (1) valid informed consent form, (2) availability of
blood samples before prostate biopsy and (3) availability of
complete clinical and serum PSA data for each patient.
Patients with other malignancies were excluded, in addition
to control group composed of 25 patients with BPH who were
recruited from the Urology Department at Kasr El-Aini
Hospital, Cairo University. And 30 apparently healthy men
based on clinical and laboratory examinations with no history
of malignant prostate disease, with PSA values less than 4 ng/
ml, and no symptoms of BPH at all.
Ethics statement
Informed written consent was taken from all participants prior
to enrollment in this study according to Human Ethics Com-
mittee approval. The study protocol was reviewed and
approved by the Ethical Committee of NCI., Cairo University
(IRB No. 00004025) and (FWA No 00007284).
Blood collection and DNA isolation
Peripheral venous blood of 3 ml was collected into EDTA con-
taining tubes and processed within 2 h after venipuncture. To
ensure cell-free plasma collection and to prevent cellular con-
tamination, all EDTA-blood samples were centrifuged in 2
steps (3000 rpm for 10 min and then 12,000 rpm for 10 min).
The cell-free plasmas were stored at 20 C until extraction.
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using QIAamp DNA Blood Mini Kits (Qiagen, Valencia,
CA) according to the manufacturer’s instruction. DNA con-
centration was measured by Nanodrop spectrophotometer,
then stored at 20 C until further analysis. T-PSA & F-
PSA were measured by a solid-phase, two-site sequential
chemiluminescent immunometric assay performed on i1000
Architect autoanalyzer. The analyzer and Kits were purchased
from Abott Architect diagnostics.
Measurement of plasma cfDNA concentration and DNA
integrity
The amount of DNA was determined by a quantitative real-
time PCR technique through Step One Real-Time PCR System
(Applied Biosystems), according to the method of [19] which
uses a set of primers to amplify the consensus ALU sequence.
A set of primers for the 115-bp amplicons were designed to
amplify both shorter and long DNA fragments representing
the total amount of cfDNA. A second set of primers for the
247-bp amplicons were also designed to amplify only long
DNA fragments representing the DNA released from non-
apoptotic cells. The sequences of the ALU 115 primers were
forward 50CCTGAGGTCAGGAGTTCGAG-30 and reverse
50CCCGAGTAGCTGGGATTACA-30; ALU 247 primers
were forward 50-GTGGCTCACGCCTGTAATC-30 and
reverse 50CAGGCTGGAGTGCAGTGG-30. DNA integrity
was calculated as the ratio of concentrations in each assay
(concentration of 247-bp fragments/concentration of 115-bp
fragments). Because the annealing sites of template DNA is
ALU115 are within the ALU247 annealing sites, the q-PCR
ratio (DNA integrity) is 1.0 when not truncated and 0.0 when
all templates DNA is completely truncated into fragments
smaller than 247 bp.
The standard reaction volume was 25 ll consisting of 2 ll
of isolated template of DNA sample, 0.2 lmol/l of forward
and reverse primers, and 12.5 ll of SYBR Green Master Mix
(QIAGEN). The real-time PCR (q-PCR) was performed with
precycling heat activation of DNA polymerase at 95 C for
15 min, followed by 50 cycles of denaturation at 94 C for
15 s, annealing at 60 C for 30 s, and extension at 72 C for
30 s. Following ampliﬁcation, melting curve analysis was per-
formed to conﬁrm PCR product speciﬁcity and was carried
out at 95 C for 5 s, 60 C for 60 s and 95 C (0.11 C/s and 5
points per C).
The cfDNA concentrations were calculated by an external
standard curve (10 ng/ll, 1 ng/ll, 0.1 ng/ll, 0.01 ng/ll and
0.001 ng/ll) of genomic DNA obtained from Promega (catalog
number; 115701). For each plate, we used a negative control,
and mean values were calculated from duplicate reactions.
Statistical methods and sample size estimation
The sample size was calculated based on the previous paper by
Umetani et al. [19] that reported an absolute difference in free
DNA between cases and controls 0.08 ± 0.09 ng/ll using
power 80% and 5% signiﬁcance level, 24 subject in each group
would be sufﬁcient.
Data were analyzed using IBM SPSS advanced statistics
version 22 (SPSS Inc., Chicago, IL). Numerical data were
expressed as mean and standard deviation or median andrange as appropriate. Chi-square test was used to examine
the relation between qualitative variables. For not normally
distributed quantitative data, comparison between two groups
was done using Mann–Whitney test (non-parametric t-test).
Comparison between 3 groups was done using Kruskal–Wallis
test (non-parametric ANOVA) then post-Hoc ‘‘Schefe test”
was used for pair-wise comparison based on Kruskal–Wallis
distribution. The Receiver Operating Characteristic (ROC)
curve was used for prediction of cut off values. All tests were
two-tailed. A p-value <0.05 was considered signiﬁcant.
Results
Participant’s characteristics of the studied groups
Characteristics of Participant’s grouped are reported in
Table 1. The mean age was 66.1 years (range 50–90) in patients
with PC and 69.3 years (range 50–87) in patients with BPH.
The mean age was 62.2 years (range 55–76) in control cases.
There was no statistical difference in age between the three
groups (P= 0.411).
The ALU115-qPCR marker was used for the quantiﬁcation
of circulating cell-free DNA (cfDNA). Its concentration in
patients with prostate cancer (median: 407.9 ng/ll, range
103.3–881.3 ng/ll) was signiﬁcantly higher than that in
patients with BPH (median: 17.2 ng/ll, range 3.2–74.5 ng/ll)
and the control group (median: 0.1 ng/ll, range 0.01–1.6 ng/
ll with P< 0.001). The ALU247-qPCR marker allows quan-
tiﬁcation of circulating cell-free DNA originated from tumor
cells. Its concentration in patients with prostate cancer (med-
ian: 107.1 ng/ ll, range 17.3–306.1 ng/ll) was signiﬁcantly
higher than that in patients with BPH (median: 1.5 ng/ll,
range 0.3–9.1 ng/ll) and the control group (median:
0.001 ng/ll, range 0.0001–00.1 ng/ll with P< 0.001). The
integrity of cfDNA in patients with prostate cancer (median:
0.29 ng/ll, range 0.16–0.43 ng/ll) was also signiﬁcantly higher
than that in patients with BPH (median: 0.10 ng/ll, range
0.06–0.15 ng/ml) and the control group (median: 0.03 ng/ll,
range 0.01–0.05 ng/ll with P< 0.001).
In patients with prostate cancer, no statistical association
was found between ALU115 cfDNA and age (P= 0.99) Glea-
son score (P= 0.66), total serum PSA (tPSA, P= 0.21), free
serum PSA (fPSA)/tPSA (P= 0.14) and stage (P= 0.382).
Also, no statistical association was found between ALU247
and age (P= 0.786) Gleason score (P= 0.907), total serum
PSA (tPSA, P= 0.169), free serum PSA (fPSA)/tPSA
(P= 0.133) and stage (P= 0,173). Furthermore, no statistical
associations were found between integrity and age
(P= 0.756), Gleason score (P= 0.302), tPSA (P= 0.610),
free serum PSA (fPSA)/tPSA (P= 0.823) and stage
(P= 0.264). In patients with BPH, no statistical associations
were found between cfDNA or its integrity and age, tPSA,
and f/tPSA Table 1.
Patient characteristics of metastatic group
Twenty-eight patients (56%) with prostate cancer had bone
metastasis conﬁrmed by CT scan, bone scintigraphy, X-ray
or magnetic resonance. There were highly signiﬁcant
differences in ALU115-qPCR (cfDNA) between metastatic
group (median: 662.9 ng/ll, range 208.8–881.3 ng/ll) and
Table 1 Characteristics of the studied groups.
No. of patients cfDNA–ALU115
Md.(range), (ng/ll)
P value ALU247 Md.(range),
(ng/ll)
P value Integrity
(ALU247/ALU115)
P value
Prostate cancer 50 407.9
(103.3–881.3)
107.1
(17.3–306.1)
0.29
(0.16–0.43)
Age (years)
665
26 407.8
(103.3–881.3)
0.992 89.5
(26.1–306.1)
0.786 0.27
(0.17–0.40)
0.756
>65 24 402.1
(108.0–785.4)
111.6
(17.3–276.5)
0.29
(0.16–0.43)
Gleason score
5–6
8 333.5
(128.4–699.9)
0.668 116.4
(39.5–220.4)
0.907 0.30
(0.23–0.41)
0.302
7–10 42 422.2
(103.3–881.3)
100.8
(17.3–306.1)
0.28
(0.16–0.43)
tPSA (ng/ml)
610
6 312.7
(108.0–422.2)
0.210 79.4
(17.3–112.9)
0.169 0.28
(0.16–0.34)
0.610
>10 44 426.3
(103.3–881.3)
112.9
(26.1–306.1)
0.29
(0.17–0.43)
f/t PSA (%)
<15
25 251.4
(103.3–870.1)
0.140 86.3
(26.1–246.9)
0.133 0.29
(0.19–0.43)
0.823
P15 25 541.9
(108.0–881.3)
118.4
(17.3–306.1)
0.28
(0.16–0.41)
Metastatic
Yes
28 662.9
(208.8–881.3)
167.9
(39.0 –306.0)
0.30
(0.16–0.43)
No 22 187.9
(103.3–373.8)
54.5
(17.3 –119.8)
0.26
(0.17–0.39)
Stage
I, II
10 536.
(108.0–848.1)
0.382 162.1
(17.3–306.0)
0.173 0.30
(0.16–0.39)
0.264
III, IV 40 333.52
(103.3–881.3)
95.2
(26.1–276.5)
0.27
(0.17–0.43)
BPH 25 17.2
(3.2–74.5)
1.5
(0.3–9.1)
0.10
(0.06–0.15)
Age (years)
665
12 12.6
(3.2 74.5)
0.852 1.4
(0.4–8.1)
0.844 0.12
(0.07–0.15)
0.163
>65 13 19.4
(4.8–71.3)
1.5
(0.3–9.1)
0.10
(0.06–0.15)
tPSA (ng/ml)
0–4
7 9.6
(3.2–54.8)
0.518 1.3
(0.3–8.2)
0.844 0.13
(0.07–0.15)
0.163
4.01–10 11 17.2
(5.3–69.4)
1.5
(0.7–8.6)
0.11
(0.07–0.14)
>10 7 52.1
(4.8–74.5)
5.2
(0.4–9.1)
0.09
(0.06–0.13)
f/t PSA (%)
<15
9 21.68
(4.8–74.5)
0.419 1.8
(0.4–8.6)
0.522 0.09
(0.07–0.14)
0.419
P15 16 8.8
(3.2–71.2)
1.2
(0.3–9.1)
0.11
(0.06–0.15)
Md.: median, BPH: benign prostate hypertrophy, tPSA: total prostate speciﬁc antigen, fPSA: free prostate speciﬁc antigen.
238 A. Fawzy et al.non-metastatic (median: 187.9 ng/ll, range (103.3–373.8) ng/
ll) with (P< 0.001) Table 2. The ALU247-qPCR marker
showed highly signiﬁcant differences between metastatic group
(median: 167.96 ng/ll, range (39.0–306.09 h) ng/ll) and non-
metastatic (median: 54.5 ng/ll, range (17.31–119.86)) ng/ll)
with (P< 0.001). Also, its integrity showed signiﬁcant differ-
ences between metastatic group (median: 0.264 ng/ll, range
(0.168–0.388) ng/ll) and non-metastatic (median 0.299 ng/ll,
range (0.160–0.426) ng/ll) with (P< 0.05) Fig. 1. However,
no association was found between these markers and the other
clinicopathological ﬁndings, such as Gleason score, tPSA and
(fPSA)/tPSA Table 2.
For distinguishing metastatic prostate cancer, the ALU115-
qPCR (cfDNA) marker showed a sensitivity of 96.4% and a
speciﬁcity of 86.4%, while the ALU247-qPCR marker showeda sensitivity of 92.9% and a speciﬁcity of 72.7%, and the integ-
rity of cfDNA demonstrated a sensitivity of 64.3% and a speci-
ﬁcity of 63.6% for distinguishing metastatic prostate cancer
Table 3.
ROC curves were plotted for testing of both markers (the
ALU115 and ALU247 markers) as well as the integrity of
cfDNA for distinguishing between metastatic and non-
metastatic prostate cancer Fig. 2.
Discussion
Many Prostate Cancer patients experience rising prostate-
speciﬁc antigen (PSA) levels following local therapy, a condi-
tion known as biochemical recurrence (BCR). Physicians treat-
ing patients with BCR face a difﬁcult set of decisions in
Table 2 Relation between patient’s characteristics with
ALU115, ALU247 and integrity in metastatic and non-
metastatic group.
Metastatic(28)
Md.(range)
Non-metastatic(22)
Md.(range)
P-Value
Age (years) 65.0
(55.0–90.0)
66.5
(50.0–88.0)
0.660
Gleason score 8.0
(5.0–10.0)
7.0
(6.0–10.0)
0.190
tPSA (ng/ml) 31.85
(9.14–2000)
76.0
(4.10–6637.0)
0.265
f/t PSA (%) 0.17
(0.06–0.4)
0.135
(0.09–0.46)
0.645
ConcALU115 662.93
(208.84–881.30)
187.92
(103.30–373.87)
<0.001*
ConcALU247 167.96
(39.0–306.09)
54.50
(17.31–119.86)
<0.001*
Integrity 0.264
(0.168–0.388)
0.299
(0.160–0.426)
0.05*
Md.: median, tPSA: total prostate speciﬁc antigen, fPSA: free
prostate speciﬁc antigen.
* Signiﬁcant p value.
Cell free DNA levels in metastatic prostate cancer 239attempting to delay the onset of metastatic disease and death
while avoiding over-treating patients whose disease may never
affect their overall survival or quality of life. Prostate cancerFigure 1 Box plots of the DNA concentrations in metastatic PC anhas a high propensity to metastasize to bones tissue and cause
osteolysis and abnormal new bone formation. On presenta-
tion, up to 30–50% of patients have bone metastasis [20].
Metastasis can even occur with asymptomatic patients with
well or moderately differentiated prostate cancers, presenting
with a serum PSA <20 ng/ml [21]. So, clinical behavior of
prostate cancer is misleading, as it can range from a micro-
scopic, well-differentiated tumor that may never be clinically
signiﬁcant to aggressive, invasive cancer that ultimately results
in metastases, morbidity, and death [22]. Hence, the effective
management requires a reliable biomarker in order to balance
the morbidity and efﬁcacy of proposed treatments against the
risks of metastatic progression.
To the best of our knowledge, this is the ﬁrst study to inves-
tigate the signiﬁcance of cfDNA and DNA integrity using
ALU sequence in plasma from Egyptian patients with Prostate
Cancer either metastatic or non-metastatic and control group
composed of benign prostate hyperplasia (BPH) and healthy
persons.
Our study shows that cfDNA ALU115 had an area under
the curve of 0.98 with the highest sensitivity of 96.4%, speci-
ﬁcity of 86.4%, PPV 90% and NPV 95% at a cutoff 259.7,
among the other studied markers for discriminating metastatic
from non-metastatic patients. Since circulating tumor DNA
comprises between 0.01% and 90% of cfDNA fragments
which are theoretically released from all tumor sites (primary
tumors, lymph node metastases, distant metastases) and fromd non-metastatic, (A) ALU115, (B) 247 and DNA integrity (C).
Table 3 Diagnostic accuracy of the studied tumor markers between metastatic and non-metastatic either single or combined.
Cutoﬀ Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Diagnostic accuracy
ALU115a 259.7 96.4 86.4 90.0 95.0 92.0
ALU247b 89.5 92.9 72.7 81.3 88.9 84.0
Integrityc 0.288 64.3 63.6 69.2 58.3 64.0
T-PSAd 10 92.9 18.2 59.1 66.7 60.0
T-PSA+ ALU115 – 89.3 90.90 92.6 87.0 90.0
T-PSA+ ALU247 – 89.3 81.8 86.2 85.7 86.0
T-PSA+ Integrity – 57.1 68.2 69.6 55.6 62.0
PPV positive predictive value, NPV negative predictive value, LR+ positive likelihood ratio, LR negative likelihood ratio, T-PSA total
prostate speciﬁc antigen.
Figure 2 Receiver operating characteristics curve for distinguishing of metastatic prostate cancer by using ALU 115 (A), ALU247 (B),
and DNA integrity (C).
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Cell free DNA levels in metastatic prostate cancer 241all parts of each tumor site [2], cfDNA (ALU115 qpcr) can be
considered as a reliable witness of the whole tumor burden and
can therefore be used as a means to monitor prostate cancer
aggressiveness, including metastatic potential, under
treatment.
Barry et al. revealed that high cfDNA concentration is due
to decreased DNAse activity, LOH and genetic aberrations
such as allelic imbalance (AI) and epigenetic changes of pro-
moter hypermethylation that was detected in cfDNA of pros-
tate cancer patients [23].
That may be explained by the fact that DNA released from
malignant tumors into the bloodstream was enhanced by
blood ﬂow through the tumors enabled dissemination of viable
tumor cells and enhanced diffusion of DNA released from
dead tumor cells into the blood stream. [24]. This feature could
correspond well with tumor activity or tumor burden.
Schwarzenbach et al. observed the correlations between
plasma DNA and Circulating Tumor Cells (CTC) in cancer
prostate patients [2]. They explained this interesting ﬁnding
by the assumption that cell free tumor DNA in the peripheral
blood may not only be derived from the primary tumor but
also from circulating or disseminated tumor cells. Tumor cells
were found to disseminate throughout the body early before
the primary tumor has acquired multiple genomic changes
and the DTCs (Disseminated Tumor Cells) can acquire key
molecular changes that may allow them to form an overt
metastasis.
Jung et al. stated that 11 of 30 patients with lymph node
metastases had increased DNA concentrations associated only
in one case with increased osteoprotegerin concentration as
distant metastatic indicator in prostate cancer patients [25].
So, an elevated DNA concentration could indicate metastatic
processes already in the early lymph node status.
The data obtained in the present study run in full agreement
with the majority of researches which detected higher levels of
cfDNA in patients with adverse prognosis or increased with
metastasis [13,26] and were predictive of PC speciﬁc survival
in patients with metastatic disease [25]. Thus, cfDNA
(ALU115 qpcr) can be considered as an important non-
invasive and useful biomarker especially for follow up in
patients with prostate cancer [15,25].
Our results showed no correlation of any of our markers
with the clinicopathological parameters as age, Gleason score,
total PSA and free PSA. These results agree with the previ-
ously obtained data by [25,27,28].
The present study shows that cfDNA ALU 247 is signiﬁ-
cantly higher in metastatic patients than the non-metastatic
group. The results are in accordance with [13,29]. Moreover,
its integrity can be useful to lesser extent with an area under
the curve of 0.65 to discriminate between metastatic patients
and the non-metastatic group, in agreement with a study done
by Delgado et al. [27] for characterization of cell-free circulat-
ing DNA in plasma in patients with prostate cancer. Their
ﬁndings suggested that the principal source of cell-free circulat-
ing DNA in cancer patients is of apoptotic and non-apoptotic
cell death; however, after 6 months of treatment, patients
demonstrated DNA released only at non-apoptotic cell death.
However, quantiﬁcation of circulating cell-free DNA still
has some limitations such as the differences in methodology
and the lack of standardization in these methodologies, which
have hampered the implementation of these tumor markers in
clinical practice. For instance, several studies use plasma toquantify the circulating cell-free DNA, while other studies
use serum as a template. [19]. Moreover, some studies per-
formed DNA extraction and measures the levels of circulating
cell-free DNA by qPCR, while other studies use serum or
plasma as a direct template to quantify cell-free DNA
[30,31]. However, most of published reports considered integ-
rity of serum and/or plasma cfDNA as a promising molecular
biomarker for detecting various types of malignancies.
In conclusion our results revealed a highly signiﬁcant level
of cfDNA and its integrity in plasma of PC patients compared
to BPH. The ALU115 qpcr is superior to ALU247 qpcr or its
integrity in discriminating metastatic patients. Therefore, the
cfDNA (ALU115 qpcr) may become a valuable non-invasive
biomarker for screening and monitoring metastasis in cancer
prostate patients, as it provides a simple and inexpensive mea-
sure for cancer detection and follow up.Recommendations
Increasing sample size, follow-up patients, correlate with sur-
vival and the response to treatment or changes in PSA levels
with the cfDNA concentrations.Conflict of interest
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